Mainz Biomed N.V. (“Mainz Biomed”) , a molecular genetics diagnostic company specializing in the early detection of cancer, ...

Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its ...

Gabbi’s telehealth solution provides logistics and educational support to assess breast cancer risk. Patients identified as potentially high risk are connected with a Gabbi clinician to be evaluated ...

RNA sequencing has emerged as a powerful supplement to DNA sequencing for Mendelian disease diagnosis, but clinical ...

BERKELEY, Calif. and MAINZ, Germany, March 03, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the ...

Molecular detection technologies help scientists rapidly and reliably find and address ever-evolving pathogens with optimal accuracy and sensitivity.

and MAINZ, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early ...

SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of ...

Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that ...

BERKELEY, US and MAINZ, Germany – March 3, 2025 - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of ...